|
End-of-day quote
Shanghai S.E.
2026-09-01
|
5-day change | 1st Jan Change | ||
| 18.41 CNY | -0.22% |
|
+6.05% | +4.48% |
| 08-24 | DaShenLin Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2026 | CI |
| 04-24 | Dashenlin Pharma's Q1 Profit Rises 11% | MT |
| Fiscal Period: December | 2016 (CNY) | 2017 (CNY) | 2018 (CNY) | 2019 (CNY) | 2020 (CNY) | 2021 (CNY) | 2022 (CNY) | 2023 (CNY) | 2024 (CNY) | 2025 (CNY) |
|---|---|---|---|---|---|---|---|---|---|---|
Profitability | ||||||||||
Return on Assets | 4.64 | 5.2 | 4.99 | 3.83 | 4.81 | |||||
Return on Total Capital | 7.57 | 8.27 | 8.24 | 6.38 | 8.39 | |||||
Return On Equity % | 13.98 | 16.86 | 16.63 | 12.19 | 16.18 | |||||
Return on Common Equity | 14.57 | 17.72 | 17.9 | 13.33 | 17.32 | |||||
Margin Analysis | ||||||||||
Gross Profit Margin % | 38.03 | 37.76 | 35.61 | 34.25 | 34.22 | |||||
SG&A Margin | 30.95 | 29.51 | 27.75 | 28.02 | 26.23 | |||||
EBITDA Margin % | 7.73 | 8.42 | 8.22 | 11.82 | 8.37 | |||||
EBITA Margin % | 6.63 | 7.52 | 7.4 | 5.93 | 7.48 | |||||
EBIT Margin % | 6.57 | 7.47 | 7.32 | 5.84 | 7.4 | |||||
Income From Continuing Operations Margin % | 4.8 | 5.08 | 5.02 | 3.7 | 4.94 | |||||
Net Income Margin % | 4.72 | 4.87 | 4.76 | 3.45 | 4.49 | |||||
Net Avail. For Common Margin % | 4.72 | 4.87 | 4.76 | 3.45 | 4.49 | |||||
Normalized Net Income Margin | 3.42 | 3.84 | 3.81 | 2.9 | 3.82 | |||||
Levered Free Cash Flow Margin | 2.46 | 10.3 | 9.22 | 7.84 | 14.02 | |||||
Unlevered Free Cash Flow Margin | 3.25 | 10.99 | 9.83 | 8.43 | 14.45 | |||||
Asset Turnover | ||||||||||
Asset Turnover | 1.13 | 1.11 | 1.09 | 1.05 | 1.04 | |||||
Fixed Assets Turnover | 4.83 | 3.62 | 3.66 | 3.63 | 3.91 | |||||
Receivables Turnover (Average Receivables) | 27.7 | 24.07 | 21.22 | 20.39 | 20.77 | |||||
Inventory Turnover (Average Inventory) | 3.29 | 3.53 | 3.92 | 4.19 | 4.38 | |||||
Short Term Liquidity | ||||||||||
Current Ratio | 1.1 | 1.1 | 0.94 | 0.92 | 0.89 | |||||
Quick Ratio | 0.56 | 0.62 | 0.54 | 0.58 | 0.57 | |||||
Operating Cash Flow to Current Liabilities | 0.22 | 0.39 | 0.28 | 0.23 | 0.36 | |||||
Days Sales Outstanding (Average Receivables) | 13.18 | 15.17 | 17.2 | 17.95 | 17.57 | |||||
Days Outstanding Inventory (Average Inventory) | 110.93 | 103.53 | 93.05 | 87.28 | 83.41 | |||||
Average Days Payable Outstanding | 144.17 | 147.23 | 147.3 | 161.24 | 185.17 | |||||
Cash Conversion Cycle (Average Days) | -20.06 | -28.54 | -37.04 | -56.01 | -84.18 | |||||
Long Term Solvency | ||||||||||
Total Debt/Equity | 88.87 | 86.41 | 82.04 | 95.16 | 66.68 | |||||
Total Debt / Total Capital | 47.05 | 46.35 | 45.07 | 48.76 | 40 | |||||
LT Debt/Equity | 70.82 | 61.94 | 59.34 | 55.82 | 31.05 | |||||
Long-Term Debt / Total Capital | 37.5 | 33.23 | 32.6 | 28.6 | 18.63 | |||||
Total Liabilities / Total Assets | 65.76 | 67.06 | 67.11 | 69.22 | 67.3 | |||||
EBIT / Interest Expense | 5.19 | 6.84 | 7.51 | 6.22 | 10.75 | |||||
EBITDA / Interest Expense | 10.57 | 12.33 | 13.48 | 12.58 | 18.8 | |||||
(EBITDA - Capex) / Interest Expense | 4.46 | 7.87 | 5.97 | 6.65 | 16.24 | |||||
Total Debt / EBITDA | 2.35 | 2.07 | 2.02 | 2.47 | 1.62 | |||||
Net Debt / EBITDA | 1.06 | 0.47 | 0.64 | 0.48 | -0.33 | |||||
Total Debt / (EBITDA - Capex) | 5.58 | 3.25 | 4.56 | 4.68 | 1.88 | |||||
Net Debt / (EBITDA - Capex) | 2.51 | 0.74 | 1.44 | 0.91 | -0.38 | |||||
Growth Over Prior Year | ||||||||||
Total Revenues, 1 Yr. Growth % | 14.92 | 26.78 | 15.45 | 8.01 | 3.8 | |||||
Gross Profit, 1 Yr. Growth % | 14.03 | 25.86 | 8.9 | 3.87 | 3.7 | |||||
EBITDA, 1 Yr. Growth % | -15.49 | 37.05 | 11.52 | -3.49 | 26.22 | |||||
EBITA, 1 Yr. Growth % | -19.12 | 42.56 | 12.28 | -14.33 | 29.31 | |||||
EBIT, 1 Yr. Growth % | -19.18 | 44.16 | 12.98 | -13.86 | 31.55 | |||||
Earnings From Cont. Operations, 1 Yr. Growth % | -25.73 | 34.17 | 14.03 | -20.37 | 38.67 | |||||
Net Income, 1 Yr. Growth % | -25.51 | 30.9 | 12.63 | -21.58 | 35.04 | |||||
Normalized Net Income, 1 Yr. Growth % | -32.37 | 42.51 | 14.34 | -17.79 | 36.79 | |||||
Diluted EPS Before Extra, 1 Yr. Growth % | -25.93 | 29.76 | 13.19 | -21.36 | 33.33 | |||||
Accounts Receivable, 1 Yr. Growth % | 72.05 | 37.37 | 20.77 | 5.61 | -1.69 | |||||
Inventory, 1 Yr. Growth % | 35.33 | 6.68 | 7.97 | -1.27 | 0.32 | |||||
Net Property, Plant and Equip., 1 Yr. Growth % | 339.24 | 7.8 | 19.79 | 0.06 | -7.47 | |||||
Total Assets, 1 Yr. Growth % | 40.58 | 20.22 | 15.75 | 9.6 | 0.18 | |||||
Tangible Book Value, 1 Yr. Growth % | -21.37 | 14.68 | -39.55 | -27.55 | 37.52 | |||||
Common Equity, 1 Yr. Growth % | 1.74 | 13.38 | 9.85 | 1.08 | 6.82 | |||||
Cash From Operations, 1 Yr. Growth % | -20.42 | 141.58 | -15.51 | -2.13 | 72.24 | |||||
Capital Expenditures, 1 Yr. Growth % | 63.44 | -20.09 | 73.62 | -17.86 | -67.19 | |||||
Levered Free Cash Flow, 1 Yr. Growth % | -44.26 | 430.76 | 3.2 | -8.09 | 85.93 | |||||
Unlevered Free Cash Flow, 1 Yr. Growth % | -27.06 | 328.31 | 3.19 | -7.34 | 78.27 | |||||
Dividend Per Share, 1 Yr. Growth % | -25.01 | 43.97 | -38 | 100 | 33.87 | |||||
Compound Annual Growth Rate Over Two Years | ||||||||||
Total Revenues, 2 Yr. CAGR % | 22.65 | 20.71 | 20.99 | 11.67 | 5.88 | |||||
Gross Profit, 2 Yr. CAGR % | 20.51 | 19.8 | 17.07 | 6.36 | 3.79 | |||||
EBITDA, 2 Yr. CAGR % | 10.62 | 8.04 | 24.26 | 31.59 | -15.76 | |||||
EBITA, 2 Yr. CAGR % | 9.38 | 7.86 | 27.25 | -1.41 | 5.88 | |||||
EBIT, 2 Yr. CAGR % | 9.63 | 7.94 | 27.72 | -1.35 | 6.45 | |||||
Earnings From Cont. Operations, 2 Yr. CAGR % | 7.46 | -0.17 | 23.69 | -4.71 | 5.08 | |||||
Net Income, 2 Yr. CAGR % | 6.12 | -1.25 | 21.42 | -6.02 | 2.9 | |||||
Normalized Net Income, 2 Yr. CAGR % | 0.26 | -1.83 | 27.77 | -3.05 | 6.05 | |||||
Diluted EPS Before Extra, 2 Yr. CAGR % | 4.44 | -1.57 | 21.3 | -5.65 | 2.4 | |||||
Accounts Receivable, 2 Yr. CAGR % | 44.61 | 53.74 | 28.8 | 12.93 | 1.9 | |||||
Inventory, 2 Yr. CAGR % | 32.91 | 20.15 | 7.32 | 3.25 | -0.48 | |||||
Net Property, Plant and Equip., 2 Yr. CAGR % | 124.76 | 117.61 | 13.64 | 9.48 | -3.78 | |||||
Total Assets, 2 Yr. CAGR % | 41.39 | 30 | 17.96 | 12.63 | 4.78 | |||||
Tangible Book Value, 2 Yr. CAGR % | -1.81 | -5.04 | -16.74 | -33.82 | -0.19 | |||||
Common Equity, 2 Yr. CAGR % | 13.67 | 7.41 | 11.6 | 5.37 | 3.91 | |||||
Cash From Operations, 2 Yr. CAGR % | -4.58 | 38.66 | 42.87 | -9.07 | 29.83 | |||||
Capital Expenditures, 2 Yr. CAGR % | 60.71 | 14.28 | 17.79 | 19.42 | -48.01 | |||||
Levered Free Cash Flow, 2 Yr. CAGR % | -37.39 | 72 | 134.12 | -2.61 | 30.58 | |||||
Unlevered Free Cash Flow, 2 Yr. CAGR % | -28.71 | 76.75 | 110.31 | -2.22 | 28.39 | |||||
Dividend Per Share, 2 Yr. CAGR % | 9.55 | 3.92 | -5.52 | 11.36 | 63.63 | |||||
Compound Annual Growth Rate Over Three Years | ||||||||||
Total Revenues, 3 Yr. CAGR % | 23.68 | 24.01 | 18.93 | 16.5 | 8.98 | |||||
Gross Profit, 3 Yr. CAGR % | 20.06 | 22.27 | 16.05 | 12.5 | 5.46 | |||||
EBITDA, 3 Yr. CAGR % | 15.95 | 19.12 | 9.56 | 33.84 | 8.38 | |||||
EBITA, 3 Yr. CAGR % | 15.3 | 19.84 | 9.74 | 11.91 | 8.35 | |||||
EBIT, 3 Yr. CAGR % | 15.53 | 20.11 | 9.65 | 12.01 | 8.58 | |||||
Earnings From Cont. Operations, 3 Yr. CAGR % | 15.23 | 15.72 | 4.35 | 6.8 | 7.98 | |||||
Net Income, 3 Yr. CAGR % | 14.17 | 13.81 | 3.17 | 4.95 | 6.05 | |||||
Normalized Net Income, 3 Yr. CAGR % | 8.64 | 12.73 | 3.35 | 10.3 | 8.74 | |||||
Diluted EPS Before Extra, 3 Yr. CAGR % | 12.18 | 12.58 | 3.19 | 4.99 | 5.88 | |||||
Accounts Receivable, 3 Yr. CAGR % | 38.11 | 42.16 | 41.85 | 20.55 | 7.83 | |||||
Inventory, 3 Yr. CAGR % | 24.39 | 23.52 | 15.95 | 4.38 | 2.26 | |||||
Net Property, Plant and Equip., 3 Yr. CAGR % | 79.16 | 75.94 | 78.34 | 8.92 | 3.51 | |||||
Total Assets, 3 Yr. CAGR % | 38.42 | 33.95 | 25.06 | 15.11 | 8.32 | |||||
Tangible Book Value, 3 Yr. CAGR % | 7.8 | 3.4 | -18.31 | -20.51 | -15.55 | |||||
Common Equity, 3 Yr. CAGR % | 21.72 | 13.58 | 8.21 | 7.98 | 5.85 | |||||
Cash From Operations, 3 Yr. CAGR % | 21.19 | 30.05 | 17.55 | 25.94 | 12.51 | |||||
Capital Expenditures, 3 Yr. CAGR % | 32.68 | 27.32 | 31.38 | 4.45 | -22.29 | |||||
Levered Free Cash Flow, 3 Yr. CAGR % | 8.58 | 27.66 | 45.11 | 71.43 | 20.73 | |||||
Unlevered Free Cash Flow, 3 Yr. CAGR % | 17.36 | 29.6 | 47.76 | 60.03 | 19.37 | |||||
Dividend Per Share, 3 Yr. CAGR % | 15.97 | 20.01 | -12.52 | 21.31 | 18.4 | |||||
Compound Annual Growth Rate Over Five Years | ||||||||||
Total Revenues, 5 Yr. CAGR % | 21.72 | 23.42 | 22.59 | 18.92 | 13.53 | |||||
Gross Profit, 5 Yr. CAGR % | 20.39 | 21.91 | 18.86 | 15.64 | 10.98 | |||||
EBITDA, 5 Yr. CAGR % | 14.4 | 19.72 | 19.39 | 24.21 | 8.47 | |||||
EBITA, 5 Yr. CAGR % | 12.69 | 19.48 | 20.15 | 11.09 | 8.4 | |||||
EBIT, 5 Yr. CAGR % | 12.68 | 19.55 | 20.26 | 11.05 | 8.36 | |||||
Earnings From Cont. Operations, 5 Yr. CAGR % | 13.42 | 17.86 | 18.54 | 7.07 | 4.64 | |||||
Net Income, 5 Yr. CAGR % | 12.96 | 16.87 | 17.02 | 5.42 | 3.06 | |||||
Normalized Net Income, 5 Yr. CAGR % | 9.5 | 15.65 | 15.92 | 6.17 | 4.42 | |||||
Diluted EPS Before Extra, 5 Yr. CAGR % | 9.49 | 14.21 | 15.93 | 4.94 | 2.87 | |||||
Accounts Receivable, 5 Yr. CAGR % | 29.18 | 32.89 | 34.31 | 29.66 | 24.27 | |||||
Inventory, 5 Yr. CAGR % | 22.71 | 17.67 | 17.26 | 14.97 | 9.07 | |||||
Net Property, Plant and Equip., 5 Yr. CAGR % | 55.33 | 50.04 | 49.33 | 45.53 | 39.34 | |||||
Total Assets, 5 Yr. CAGR % | 37.09 | 29.05 | 29.84 | 24.98 | 16.52 | |||||
Tangible Book Value, 5 Yr. CAGR % | 20.02 | 5.33 | -2.78 | -13.5 | -11.49 | |||||
Common Equity, 5 Yr. CAGR % | 32.98 | 17.68 | 17.57 | 10.22 | 6.47 | |||||
Cash From Operations, 5 Yr. CAGR % | 25.7 | 42.12 | 29.43 | 12.71 | 22.32 | |||||
Capital Expenditures, 5 Yr. CAGR % | 33.33 | 9.13 | 26.51 | 24.1 | -9.33 | |||||
Levered Free Cash Flow, 5 Yr. CAGR % | 17.16 | 206.44 | 47.65 | 14.57 | 39.11 | |||||
Unlevered Free Cash Flow, 5 Yr. CAGR % | 22.81 | 160.21 | 48.2 | 15.8 | 39.68 | |||||
Dividend Per Share, 5 Yr. CAGR % | - | 17.57 | 6.85 | 16.47 | 12.38 |
Select your edition
All financial news and data tailored to specific country editions
















